Drug developers have been fishing in the bumpy RNA interference (RNAi) waters for years without a catch in sight. They probably won’t have to wait much longer. In December 2017, RNAi pioneer Alnylam Pharmaceuticals…

Click here to original publication.

Fonte: 156 | MARCH 2018 | VOLUME 17 www.nature.com/nrd